Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
News|Articles|June 2, 2005
- Pharmaceutical Technology-06-02-2005
- Volume 29
- Issue 6
June 2005
Author(s)Pharmaceutical Technology Editors
Pharmaceutical science and technology news.
Advertisement
Articles in this issue
over 21 years ago
In the Spotlight: Pharmaceutical Science & Technology Innovationsover 21 years ago
June 2005over 21 years ago
Tragedy of the CommonsDouglas McCormickover 21 years ago
Seeking a Fresh Startover 21 years ago
Drug Specifications Under ScrutinyJill Wechslerover 21 years ago
Revisiting The Notion Of Singlet Testing Requirementsover 21 years ago
New Systems for Counterfeit Protection and Quality ControlAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
Advertisement
Advertisement